inVentiv Health Establishes Operation in Korea

                inVentiv Health Establishes Operation in Korea

  PR Newswire

  BURLINGTON, Mass., Nov. 9, 2011

BURLINGTON, Mass., Nov. 9, 2011 /PRNewswire/ -- inVentiv Health, Inc.,
offering best-in-class clinical, commercial and consulting services to the
healthcare industry, today announced that it has established inVentiv Health
Korea, a Seoul-based operation that will provide clinical development and
commercial services to healthcare clients.

inVentiv Health Korea will deliver outsourced sales services through the
company's Selling Solutions segment. inVentiv has recently signed an agreement
with a top-20, multi-national pharmaceutical company to provide medical
representatives to promote several of its products in Korea. In addition,
inVentiv Health Korea is already providing clinical development services to
several pharmaceutical clients through its clinical segment, PharmaNet/i3.

"Our clients are expanding their businesses in Asia and as they do, inVentiv
is broadening its geographic reach to meet their outsourcing needs," said Paul
Meister, CEO of inVentiv Health, Inc. "As a $15 billion pharmaceutical market
expected to grow by significant margins over the next several years, Korea is
an attractive opportunity for us. Not only are our pharmaceutical clients
increasingly conducting clinical research in Korea, it is also a market where
many leading pharmaceutical brands in the U.S. will be launching in the coming
years, creating a growing need for outsourced sales and marketing support. Our
move into Korea also reflects our commitment to expanding inVentiv's
best-in-class services into key emerging markets."

inVentiv Health Korea will be led by Jae-Hee Kim, who will serve as President.
Mr. Kim has more than 20 years of executive leadership, new business
development, client services, and sales and marketing experience. Prior to his
current position, Mr. Kim was a Representative Director at Enters Partners Co.
Ltd., a marketing and consulting company to the pharmaceutical industry. He
has held several senior-level positions with Korean Green Cross Corporation,
SmithKline Beecham, and Quintiles Transnational. Mr. Kim graduated from the
Department of Business Administration, Chung-Ang University and received his
Executive MBA from the Helsinki School of Economics.

"Jae-Hee Kim brings a great depth of experience to this role having held
senior roles at top pharmaceutical manufacturing companies and within leading
service-side healthcare businesses. With unmatched knowledge of the Korean
marketplace, Mr. Kim is the ideal candidate to help inVentiv establish a
strong presence in this important geography," said Rick Finnegan, Executive
Vice President, Global Operations, inVentiv Health.

About inVentiv Health

inVentiv Health, Inc. is a leading global provider of best-in-class clinical,
commercial and consulting services to companies seeking to accelerate
performance. inVentiv's client roster includes more than 550 pharmaceutical,
biotech and life sciences companies. With 13,000 employees in 40 countries,
inVentiv rapidly transforms promising ideas into commercial reality. inVentiv
Health Inc. is privately owned by inVentiv Group Holdings Inc., an
organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty
Lane Partners and members of the inVentiv management team. For more
information, visit .

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks that may cause inVentiv Health's
performance to differ materially. Such risks include, without limitation: the
impact of our substantial level of indebtedness on our ability to generate
sufficient cash to fulfill our obligations under our existing debt instruments
or our ability to incur additional indebtedness; the impact of the
consummation of any announced acquisitions, and any additional leverage we may
incur in connection with the financing thereof, on the ratings of our debt
securities; our ability to sufficiently increase our revenues and maintain or
decrease expenses and cash capital expenditures to permit us to fund our
operations; our ability to continue to comply with the covenants and terms of
our credit facility and to access sufficient capital to fund our operations;
the impact of any default by any of our credit providers or swap
counterparties; our ability to accurately forecast costs to be incurred in
providing services under fixed price contracts; our ability accurately
forecast insurance claims within our self-insured programs; the potential
impact of pricing pressures on pharmaceutical manufacturers from future
healthcare reform initiatives or from changes in the reimbursement policies of
third-party payers; our ability to grow our existing client relationships,
obtain new clients and cross-sell our services; the potential impact of
financial, economic, political and other risks, including interest rate and
exchange rate risks, related to conducting business internationally; our
ability to successfully operate new lines of business; our ability to manage
our infrastructure and resources to support our growth; our ability to
successfully identify new businesses to acquire, conclude acquisition
negotiations and integrate acquired businesses, including the acquisitions of
i3 Global and PharmaNet Development Group, Inc., into our operations; any
disruptions, impairments, or malfunctions affecting software as well as
excessive costs or delays that may adversely impact our continued investment
in and development of software; the potential impact of government regulation
on us and on our client base; our ability to comply with all applicable laws
as well as our ability to successfully implement from a timing and cost
perspective any changes in applicable laws; our ability to recruit, motivate
and retain qualified personnel, including sales representatives; the
possibility that client agreements will be terminated or not renewed;
consolidation in the pharmaceutical industry; changes in trends in the
healthcare and pharmaceutical industries or in pharmaceutical outsourcing,
including initiatives by our clients to perform services we offer internally;
the potential liability associated with bringing new drugs to market,
including potential liability from injury to clinical trial participants; and
the actual impact of the adoption of certain accounting standards; our ability
to maintain technological advantages in a variety of functional areas,
including sales force automation, electronic claims surveillance and patient
compliance. Readers of this press release are referred to documents which may
be filed from time to time by inVentiv Health Inc. with the Securities and
Exchange Commission for further discussion of these and other factors.

SOURCE inVentiv Health, Inc.

Contact: Anita Bose, inVentiv Health, Inc., +1-212-462-8714,
Press spacebar to pause and continue. Press esc to stop.